CCDC185

Across TCGA pan-cancer cohorts, CCDC185 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CCDC185 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CCDC185 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC185 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, DLBC, and UCEC are the cancer types where CCDC185 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
DLBC	DFS	Median	All	0.022	0.809	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.437	.017	16	view →
COAD	DFS	Median	III,IV	0.005	0.668	<.001	12	view →
LUAD	OS	Median	All	0.090	0.788	<.001	12	view →
HNSC	OS	Median	All	0.515	0.768	.022	11	view →
LIHC	DFS	Median	III,IV	0.040	0.361	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CCDC185–THYM (OS)

Open the THYM breakdown →